Tumors Clinical Trial
Official title:
Kypho-IORT: Phase II Study for Dose Escalation of Intraoperative Radiotherapy During Kyphoplasty for Spinal Metastases
Vertebral column is the most prevalent location of bone metastases. Besides axial pain, vertebral metastases cause pathological fracture and neurological dysfunction by spinal cord compression. Although the median overall survival of patients with bone metastases is only 7-9 month, half of them live longer and will require palliative treatment for their symptoms. Treatment options are radiotherapy and /or surgical treatment such as laminectomy, vertebroplasty or kyphoplasty. Various studies have shown the superiority of postoperative external beam radiotherapy after kyphoplasty in spinal metastases compared to surgery or radiotherapy alone. Nevertheless postoperative radiation schedules last 2-4 weeks. Moreover many patients present visceral and bone metastases simultaneously and require urgent systemic therapy. However, due to potentiated toxicity, concurrent therapy with full dose chemotherapy and radiotherapy is rarely possible. The investigators have therefore established a novel method for intraoperative radiotherapy (IORT) during kyphoplasty which enables immediate stability, sterilization of the metastasis and immediate initiation of chemotherapy. The kyphoplasty itself is performed according to the standard procedure with some minor modifications. In short under general anaesthesia, a bipedicular approach into the affected vertebra is chosen with insertion of specially designed metallic sleeves to guide the electron drift tube of the miniature X-ray generator (INTRABEAM®). To perform the IORT during a kyphoplasty with this device a new applicator was designed. This sterile applicator consists of a plastic head, which is needed to attach it to the X-ray source and a stainless steel tube. This tube protects the probe from bending. Under fluoroscopic guidance the applicator including the drift tube is guided through the metallic sleeves in the vertebral body. A dose of 8 Gy in 5 mm distance is delivered. After IORT the INTRABEAM system is removed. The kyphoplasty balloon is inflated and PMMA-cement is injected. Afterwards the sleeves are removed and the wound is closed as usual. Aim of this study is the definition of the maximum tolerable dose (MTD) for IORT during a kyphoplasty using specific MTD-criteria and evaluating the effectiveness of this combined treatment procedure. To determine the MTD 3 levels with increasing doses are planned: 8 Gy in 5 mm distance, 8 Gy in 8 mm distance and 8 Gy in 10 mm distance.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT01562626 -
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00435669 -
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
|
Phase 1 | |
Completed |
NCT00375245 -
Rapamycin With Grapefruit Juice for Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00400023 -
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00410696 -
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
|
Phase 2 | |
Completed |
NCT00372437 -
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
|
Phase 1/Phase 2 | |
Completed |
NCT00395434 -
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00553033 -
Laparoscopic Liver Resection
|
N/A | |
Completed |
NCT00248404 -
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
|
Phase 1/Phase 2 | |
Completed |
NCT00207103 -
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT00222443 -
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
|
Phase 1 | |
Terminated |
NCT03251924 -
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05103969 -
Cohort of Tumors With POLE/D1 Mutation
|
||
Completed |
NCT00446446 -
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
|
Phase 2 | |
Completed |
NCT02275910 -
Phase 1 Study of E7090 in Subjects With Solid Tumor
|
Phase 1 | |
Terminated |
NCT02271516 -
to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage
|
Phase 1 | |
Completed |
NCT01448759 -
Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel
|
N/A | |
Terminated |
NCT01081808 -
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00389480 -
Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies
|
Phase 1 | |
Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 |